MNPR
Monopar Therapeutics Inc
NASDAQ: MNPR · HEALTHCARE · BIOTECHNOLOGY
$60.99
-1.14% today
Updated 2026-06-03
Market cap
$398.46M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.93
Dividend yield
—
52W range
$29 – $105
Volume
0.2M
Monopar Therapeutics Inc (MNPR) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.83M | $2.90M | $9.93M | $7.32M | $13.35M | $16.87M | $20.52M | $13.23M | $7.35M | $60.29M | $140.72M |
| Cash & equivalents | $2.01M | $2.07M | $8.98M | $6.89M | $13.21M | $16.74M | $20.30M | $8.19M | $7.27M | $45.82M | $61.83M |
| Current assets | $2.03M | $2.10M | $9.13M | $7.32M | $13.23M | $16.80M | $20.52M | $13.17M | $7.33M | $60.29M | $140.46M |
| Total liabilities | $73843.00 | $64510.00 | $311867.00 | $399551.00 | $724165.00 | $1.18M | $1.58M | $3.14M | $1.76M | $5.25M | $2.89M |
| Current liabilities | $73843.00 | $64510.00 | $311867.00 | $399551.00 | $724165.00 | $1.18M | $1.58M | $3.13M | $1.76M | $5.25M | $2.74M |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | — |
| Shareholder equity | $2.75M | $2.83M | $9.62M | $6.92M | $12.63M | $15.69M | $18.94M | $10.09M | $5.59M | $55.04M | $137.83M |
| Retained earnings | $-687311.00 | $-1.87M | $-18.43M | $-21.66M | $-25.88M | $-32.19M | $-41.29M | $-51.80M | $-60.21M | $-75.79M | $-89.51M |
| Accounts receivable | — | — | — | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — |
Frequently asked questions
How much free cash flow does MNPR generate?
MNPR produced $-12.20M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is MNPR's balance sheet healthy?
MNPR holds $61.83M in cash and equivalents against — in long-term debt, on $137.83M of shareholder equity. That debt is best read against the cash flow the business throws off each year.